Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

Nanopore Methylation Sequencing 2026 — PatSnap Eureka

Nanopore Methylation Sequencing 2026 — PatSnap Eureka
Technology Landscape · 2026

Nanopore Methylation Sequencing: 2026 Technology Landscape

Direct, bisulfite-free detection of DNA base modifications is displacing traditional sequencing methods. Explore the patent signals, computational tools, and clinical applications shaping this inflection point—powered by PatSnap Eureka intelligence.

Innovation Phase Timeline (2014–2024)
Nanopore Methylation Sequencing Innovation Phases: Foundational 2014–2016, Algorithm Development 2018–2021, Clinical Translation 2022–2024 Three-phase trajectory of nanopore methylation sequencing innovation from foundational hardware detection through deep learning algorithm development to clinical and forensic translation, based on patent and literature analysis via PatSnap Eureka. FOUNDATIONAL 2014 – 2016 HMM · MinION · CpG detection ALGORITHM DEV 2018 – 2021 CNN · RNN · >90% accuracy CLINICAL TRANS. 2022 – 2024 Liquid biopsy · Forensic · IP Dataset spans 2014–2024 · Academic & commercial patent + literature records Source: PatSnap Eureka · eureka.patsnap.com
>90%
Genome-level accuracy at 5× coverage (DeepSignal, 2018)
165×
Median coverage at 10 loci via nCATS (Johns Hopkins, 2019)
0.98
CpG methylation correlation with bisulfite sequencing (plant, 2021)
<30 min
Methylation profiling per sample on Android smartphone (Genopo, 2020)
Core Technology

How Nanopore Methylation Sequencing Works

Nanopore methylation sequencing exploits the fact that methylated bases produce measurably distinct ionic current signatures as they traverse a biological nanopore—most commonly a protein pore embedded in a lipid membrane. Unlike bisulfite conversion methods, which chemically alter the DNA template and can introduce bias in repetitive or highly homologous genomic regions, nanopore-based detection reads native, unmodified DNA directly.

The field spans three tightly coupled technical sub-domains: hardware and pore chemistry innovations enabling reliable current discrimination; computational signal-processing and machine learning tools that convert raw electrical signals into methylation calls; and enrichment and targeting strategies that increase depth at loci of interest.

The technology addresses three principal modification types: CpG-context 5mC (the dominant focus), non-CpG context 5mC relevant to plant and cancer biology, and bacterial methylation types including 6mA and N4-methylcytosine (4mC). Electrolyte chemistry remains an active zone of hardware-level IP development, as evidenced by Illumina's 2024 EP patent covering cation complexing agents and gel-state polyelectrolytes in nanopore sequencer wells.

According to EMBL-EBI and related genomics bodies, epigenome-wide profiling at scale requires both sequencing depth and modification specificity—criteria that nanopore platforms are increasingly meeting without the chemical degradation associated with bisulfite protocols.

Modification Types Detected
5-methylcytosine (5mC)
CpG context · dominant focus · cancer & EWAS
5-hydroxymethylcytosine (5hmC)
Oxidative derivative · neural tissue · emerging
N6-methyladenine (6mA)
Bacterial · microbiome · restriction-modification
N4-methylcytosine (4mC)
Bacterial · virulence regulation · de novo discovery
18 kb
Median read length in nCATS targeted sequencing
30×
Human genome coverage from 39 MinION flowcells (Utah, 2017)
~10×
Coverage for genome-wide allele-specific methylation (NanoMethPhase)
Coverage threshold for >90% DeepSignal accuracy
Data Visualisation

Key Performance Metrics from the Innovation Dataset

All figures derived from patent and literature records retrieved via PatSnap Eureka. No data is estimated or fabricated.

Plant Methylation Context Correlation with Bisulfite Sequencing

Deep learning nanopore pipeline (Central South University, 2021) achieves correlation above 0.85 across all three cytosine methylation contexts in Arabidopsis and rice.

Plant Methylation Correlation: CpG 0.98, CHG 0.96, CHH 0.85 — all above bisulfite sequencing baseline Correlation coefficients between nanopore deep learning pipeline and bisulfite sequencing for CpG (0.98), CHG (0.96), and CHH (0.85) methylation contexts in Arabidopsis thaliana and Oryza sativa. Source: Central South University, 2021, via PatSnap Eureka. 1.00 0.95 0.90 0.85 0.80 0.98 CpG 0.96 CHG 0.85 CHH Correlation Coefficient Source: Central South University (2021) · PatSnap Eureka

Geographic Distribution of Innovation Contributions

The United States leads institutional output, with Canada, Australia, Europe, and China each contributing distinct methodological advances across the 2014–2024 dataset.

Geographic Innovation Distribution: USA most heavily represented, Canada prominent, Australia notable, Europe contributing, China contributing — nanopore methylation sequencing 2014–2024 Relative distribution of key institutional contributors to nanopore methylation sequencing by geography, based on patent and literature records retrieved via PatSnap Eureka across the 2014–2024 dataset. 5 Geographies USA (most represented) Canada (prominent) Australia (notable) Europe (contributing) China (contributing) Source: PatSnap Eureka · patent & literature dataset 2014–2024

Algorithm Development Milestones by Approach

From HMM baselines to deep learning and unsupervised DTW alignment — the computational calling stack has progressed through distinct methodological generations.

Algorithm Milestones: HMM 2016 (CpG detection), DeepSignal CNN/RNN 2018 (>90% accuracy), NanoMethPhase 2021 (haplotype phasing), CpelNano 2021 (Ising model), Nadavca DTW 2023 (unsupervised) Progression of nanopore methylation calling algorithms from hidden Markov models through convolutional and recurrent neural networks to unsupervised dynamic time warping approaches, based on literature records via PatSnap Eureka. 1 2016 HMM CpG detect. 2 2018 DeepSignal CNN/RNN >90% 3 2021 NanoMethPhase Haplotype phasing 4 2021 CpelNano Ising model 5 2023 Nadavca DTW Unsupervised Ontario ICRC Clemson Univ. BC Cancer Johns Hopkins Comenius Univ. Source: PatSnap Eureka · literature dataset 2016–2023

Application Domains by Research Intensity

Oncology/liquid biopsy and EWAS lead application development. Forensic and mitochondrial epigenomics represent emerging, less-saturated domains.

Application Domains: Oncology/Liquid Biopsy (highest), EWAS, Microbiology, Plant Epigenomics, Forensic, Mitochondrial (emerging) — nanopore methylation sequencing Relative research intensity across six application domains for nanopore methylation sequencing, based on patent and literature records retrieved via PatSnap Eureka across the 2014–2024 dataset. Oncology / Liquid Biopsy Epigenome-Wide (EWAS) Microbiology / Microbiome Plant Epigenomics Forensic / Identity Mitochondrial High High Med-High Medium Emerging Emerging Source: PatSnap Eureka · patent & literature dataset 2014–2024

Run your own nanopore methylation patent search with PatSnap Eureka AI

Search Nanopore Patent Data
Technology Clusters

Four Core Innovation Clusters in Nanopore Methylation Sequencing

The retrieved dataset reveals four tightly defined technical clusters, each advancing a distinct dimension of the platform's capability.

Cluster 1

Direct Electrical Signal Detection with Statistical & ML Models

The dominant approach analyzes raw picoampere-scale ionic current signals as native DNA translocates through the nanopore. Early implementations used hidden Markov models trained on k-mer current tables. PatSnap Analytics tracks how these models evolved: DeepSignal (Clemson, 2018) introduced CNN and RNN architectures, exceeding HMM accuracy for both 6mA and 5mC. The 2023 Nadavca tool from Comenius University advances unsupervised detection via dynamic time warping (DTW) improvements, reducing dependence on large labeled training datasets.

DeepSignal >90% accuracy at 5× coverage
Cluster 2

Targeted Enrichment Strategies for Locus-Specific Methylation

Whole-genome approaches provide breadth but low depth. Johns Hopkins' nCATS method (2019) uses Cas9 to introduce sequence-specific cuts and ligate nanopore adaptors directly, achieving median 165× coverage at 10 genomic loci with median read length of 18 kb—preserving base modification information absent in amplification-based methods. The University of Essex (2022) validated CRISPR-Cas9 targeted nanopore sequencing covers more than 97% of the genome versus less than 3% for Illumina EPIC microarrays. Nanopore adaptive sampling (Australian National University, 2023) enables real-time computational enrichment without wet-lab chemistry.

165× median coverage via nCATS
Cluster 3

Haplotype-Resolved and Allele-Specific Methylation Phasing

Long nanopore reads enable co-detection of SNPs and methylation on the same DNA molecule, enabling phased epigenome analysis inaccessible to short-read methods. BC Cancer's NanoMethPhase tool (2021) phases 5mC from long reads with SNVoter post-processing for improved SNV accuracy in low-coverage regions, enabling genome-wide allele-specific methylation detection at approximately 10× coverage. Johns Hopkins' CpelNano (2021) uses an HMM with Ising probability distributions to model methylation landscapes accounting for nanopore measurement noise. The University of Utah (2017) demonstrated simultaneous structural variant detection and epigenetic calling from ultra-long reads in a 30× human genome assembly.

Megabase-scale phasing at ~10× coverage
Cluster 4

Multi-Modification Discovery in Microbial & Non-CpG Contexts

A distinct cluster extends beyond mammalian CpG methylation to systematic detection of all three canonical bacterial methylation types and plant non-CpG methylation. Mount Sinai's nanodisco tool (2021) couples identification and fine mapping of 6mA, 5mC, and 4mC in a multi-label classification framework applied to individual bacteria and the mouse gut microbiome. Central South University's deep learning pipeline (2021) detects 5mC in CpG, CHG, and CHH contexts in plant genomes with correlations above 0.98 (CpG), 0.96 (CHG), and 0.85 (CHH) versus bisulfite sequencing in Arabidopsis and rice. The TMA-NP sensor (Northwest University Xi'an, 2017) uses tetramethylammonium chloride electrolyte to amplify methyl-cytosine-guanine current signatures without bisulfite, enzyme amplification, or chemical modification.

6mA, 5mC, 4mC multi-label classification
PatSnap Eureka

Map the full nanopore methylation IP landscape

Identify white space, track assignee activity, and benchmark computational tools with AI-powered patent intelligence.

Explore IP Landscape Now
Application Domains

Where Nanopore Methylation Sequencing Is Being Deployed

From oncology liquid biopsy to forensic identity science, six distinct application tracks are evidenced in the 2014–2024 dataset.

Application Domain Key Institution(s) Year Core Capability Demonstrated Status
Oncology / Liquid Biopsy Hebrew University of Jerusalem 2021 cfDNA: cancer-specific methylation, copy number alterations, and fragmentation signatures from a single shallow ONT run Active
Epigenome-Wide Association (EWAS) University of Essex; Weill Cornell Medicine; University of Connecticut 2021–2022 Nanopore covers >97% genome vs <3% for EPIC array; seven-tool benchmark establishes quantitative standards Active
Plant Epigenomics / Agriculture Central South University 2021 Multi-context (CpG/CHG/CHH) detection in Arabidopsis and rice; correlations >0.85 with bisulfite sequencing Growing
Microbiology / Microbiome Icahn School of Medicine at Mount Sinai 2020–2021 De novo discovery of 6mA, 5mC, 4mC across individual bacteria and mouse gut microbiome using nanodisco Growing
Forensic & Identity Science Australian National University 2023 Age-associated and body-fluid-specific methylation markers profiled simultaneously via adaptive sampling in a single assay Emerging
Mitochondrial Epigenomics University of Luxembourg 2021 CpG methylation detection in mtDNA using nanopore long reads and Nanopolish, bypassing bisulfite conversion biases Emerging

Track application-domain patent activity in real time

PatSnap Eureka monitors new filings across all six domains as they publish.

Monitor Domain IP Signals
Emerging Directions

Five Active Trajectories Shaping the 2022–2024 Frontier

Based on the most recent filings and publications in this dataset, these directions show the clearest momentum toward clinical and commercial translation.

🎯

Adaptive Sampling for Targeted Methylation Without Wet-Lab Enrichment

The 2023 Australian National University study demonstrates real-time computational enrichment using nanopore adaptive sampling, enabling simultaneous capture of multiple methylation marker classes without restriction enzymes, affinity pulldown, or CRISPR cutting. This represents a shift from wet-lab enrichment toward software-driven selectivity.

⚗️

Electrolyte and Pore Chemistry Engineering for Improved Discrimination

Illumina's 2024 EP patent covering modified electrolytes—cation complexing agents and gel-state polyelectrolytes—in nanopore cis/trans wells indicates hardware-level IP development is ongoing to improve ionic signal contrast between modified and unmodified bases. This signals competitive entry by the incumbent short-read market leader.

🔬

Unsupervised Signal Modeling for Novel Modification Discovery

The 2023 Comenius University Nadavca tool advances unsupervised methylation detection through improved dynamic time warping (DTW) signal alignment, reducing dependence on large labeled training datasets. This is especially relevant for detecting non-canonical or novel epigenetic marks where labeled reference data is unavailable.

🩸

Liquid Biopsy: Co-Detection of Methylation, Copy Number, and Fragmentation

The Hebrew University of Jerusalem (2021) cfDNA study integrates methylation calling, copy number alteration detection, and fragmentation analysis from a single shallow nanopore run. This multi-analyte approach from a single sequencing run represents a trajectory toward compact clinical liquid biopsy panels.

🔒
Unlock Mobile Diagnostics & IP White Space Analysis
See the full emerging directions analysis including point-of-care methylation and multi-modification IP gap mapping.
Genopo mobile pipeline 5hmC / 6mA IP gaps + white space signals
Access Full Landscape →
Strategic Intelligence

What the Patent and Literature Signals Mean for R&D Teams

Bisulfite sequencing displacement is underway but not complete. Among retrieved results, nanopore methylation detection is consistently benchmarked against bisulfite sequencing and Illumina EPIC arrays. The 2022 University of Essex study demonstrates that nanopore achieves genuine genome-wide coverage while avoiding bisulfite-associated DNA degradation and mapping ambiguity in repetitive regions. R&D teams should plan migration strategies for existing bisulfite-based EWAS pipelines, particularly for repetitive genomic regions and allele-specific methylation studies.

Computational tool fragmentation remains a bottleneck. Benchmark studies from Weill Cornell Medicine and the University of Connecticut (both 2021) identified performance differences between seven independent calling tools across genomic contexts, coverage levels, and modification types. IP strategists and product developers should track consolidation signals—either through commercial licensing of leading tools (DeepSignal, Nanopolish, Megalodon) or integration into ONT's native basecalling stack. The PatSnap life sciences intelligence platform monitors such consolidation events as they occur.

Illumina's active 2024 EP patent on modified-electrolyte nanopore sequencer hardware is a strategic signal that the incumbent short-read market leader is building nanopore IP assets—representing either a defensive IP posture or preparation for a competitive product launch. According to EPO filing data, active European patents in sequencing hardware continue to grow year-on-year. Multi-modification and non-CpG contexts remain underdeveloped IP territory, with the majority of calling tools and patents focused on CpG-context 5mC—representing white space for development teams tracking validated innovation strategies.

Key Strategic Signals
  • Bisulfite displacement underway—plan EWAS pipeline migration
  • Seven competing calling tools—track consolidation signals
  • Illumina 2024 EP patent signals hardware competitive entry
  • nCATS and adaptive sampling highest clinical translation potential
  • 5hmC, 6mA, 4mC detection remains underdeveloped IP territory
  • Mobile/PoC methylation diagnostics pathway validated (Genopo, 2020)
Map IP White Space
Commercial IP Signals
Illumina Inc. — EP Active (2024)
Modified electrolyte nanopore sequencer hardware
Genia Technologies — EP Active (2019)
Tag-molecule detection for nanopore sequencing
Academic Institutions
Predominantly academic-driven in this dataset
Frequently asked questions

Nanopore Methylation Sequencing — key questions answered

Still have questions? Let PatSnap Eureka answer them for you.

Ask PatSnap Eureka AI
PatSnap Eureka

Accelerate Your Nanopore Epigenomics R&D with AI Patent Intelligence

Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map methylation sequencing IP white space, track competitor filings, and benchmark computational tools—all in one platform.

References

  1. Detecting DNA Methylation using the Oxford Nanopore Technologies MinION sequencer — Ontario Institute for Cancer Research, 2016
  2. DeepSignal: detecting DNA methylation state from Nanopore sequencing reads using deep-learning — Clemson University, 2018
  3. Megabase-scale methylation phasing using nanopore long reads and NanoMethPhase — BC Cancer, Michael Smith Genome Sciences Centre, 2021
  4. Targeted Nanopore Sequencing with Cas9 for studies of methylation, structural variants, and mutations — Johns Hopkins University, 2019
  5. DNA methylation-calling tools for Oxford Nanopore sequencing: a survey and human epigenome-wide evaluation — University of Connecticut / Jackson Laboratory, 2021
  6. DNA methylation calling tools for Oxford Nanopore sequencing: a survey and human epigenome-wide evaluation — Weill Cornell Medicine, 2021
  7. Discovering multiple types of DNA methylation from bacteria and microbiome using nanopore sequencing — Icahn School of Medicine at Mount Sinai, 2021
  8. Evaluation of nanopore sequencing for epigenetic epidemiology: a comparison with DNA methylation microarrays — University of Essex, 2022
  9. Estimating DNA methylation potential energy landscapes from nanopore sequencing data (CpelNano) — Johns Hopkins University, 2021
  10. Genome-wide Detection of Cytosine Methylations in Plant from Nanopore sequencing data using Deep Learning — Central South University, 2021
  11. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing — Hebrew University of Jerusalem, 2021
  12. Analysis of mitochondrial genome methylation using Nanopore single-molecule sequencing — University of Luxembourg, 2021
  13. Methylartist: tools for visualizing modified bases from nanopore sequence data — University of Queensland, 2022
  14. Profiling age and body fluid DNA methylation markers using nanopore adaptive sampling — Australian National University, 2023
  15. Precise Nanopore Signal Modeling Improves Unsupervised Single-Molecule Methylation Detection — Comenius University in Bratislava, 2023
  16. Fast and precise detection of DNA methylation with tetramethylammonium-filled nanopore — Northwest University Xi'an, 2017
  17. Genopo: a nanopore sequencing analysis toolkit for portable Android devices — Garvan Institute of Medical Research, 2020
  18. Nanopore sequencing and assembly of a human genome with ultra-long reads — University of Utah, 2017
  19. European Patent Office (EPO) — Sequencing Hardware Patent Filings
  20. EMBL-EBI — Epigenomics Data Resources and Standards
  21. NCBI / NIH — Bisulfite Sequencing and Epigenomics Literature

All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about nanopore methylation sequencing.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka